Conversion Treatment in Unresectable Colorectal Cancer with Synchronous Liver Metastases Using Hepatic Artery Infusion Plus Systemic Chemotherapy

Conversion Treatment in Unresectable Colorectal Cancer with Synchronous Liver Metastases Using Hepatic Artery Infusion Plus Systemic Chemotherapy - Treated the Synchronous Liver Metastases from Colorectal Cancer with Hepatic Artery Infusion

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009528

Enrollment

Registered

2012-12-20

Start date

2013-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal liver metastases

Interventions

systymic chemotherapy with XELOX combined with HAI of FUDR and Dex systemic chemotherapy with XELOX alone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients had biopsy-proven colorectal cancer and unresectable synchronous liver metastases 2. the score of ECOG was less than 3.Age >=18 and 75=< 4.No prior surgery, radiation, chemotherapy 6.Required baseline laboratory parameters (within 14 days before registration): Hb more than 9.0g/dl WBC >= 3000 /mm3 and <= 12,000 /mm3 Neu >= 1500 / mm3 Plt >= 75,000/mm3 T-Bil <= 2.5 times ULM AST<= ULNx2.5 ALT<= ULNx2.5 Creatinine <=1.5 mg/dL 7.Written IC

Exclusion criteria

Exclusion criteria: 1.Extrahepatic metastases 2.Imminent risk of obstruction or significant bleeding due to primary cancer 3. Previous or concurrent malignancy 4.Symptomatic psychological disease 5.Unsuitable to implant HAI pump by radiologic method because of the variations of the hepatic artery anatomy evaluated by computed tomography angiography (CTA)

Design outcomes

Primary

Measure	Time frame
overall survival time	—

Secondary

Measure	Time frame
side effect, progression-free survival time; resectability rate	—

Countries

Asia(except Japan)

Contacts

Public ContactShi Liangrong

the Third Affiliated Hospital of Soochow University Oncology Department

shiliangr@126.com

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026